- Global Pharma News & Resources

Asia-Pacific Epilepsy Therapeutics Markets 2018-2024: Market will be Valued at $1.7 Billion -

The "Epilepsy Therapeutics in Asia-Pacific Markets to 2024 - Uptake of Novel Therapies and Rising Awareness is Expected to Drive the Market Growth" report has been added to's offering.

The APAC epilepsy market will be valued at $1.7 billion in 2024, growing from $1.4 billion in 2017 at a CAGR of 3.5%.

Epilepsy treatment has historically been dominated by gamma aminobutyric acid (GABA) modulators and sodium channel blockers, leaving a wide unmet need intact in a sizeable section of patients who do not respond to the existing treatment options. Historically there is a lack of potent disease modifying or curative drugs in the epilepsy therapeutic space. The dominant older generation AEDs had poor safety and tolerability profiles. Second generation AEDs with newer mechanisms of action; signaled a shift in this trend in the last decade with improved tolerability and efficacy.

The value of the market is expected to grow more rapidly in India and China compared with the more developed markets, Japan and Australia. With a high prevalence, these two regions have large treatment populations, which are expected to grow further due to better healthcare access and improvements in treatment gaps.

The late-stage pipeline contains promising therapies that have the potential to achieve approval and launch during the forecast period. These drugs are under development with novel mechanisms of actions that are not conventional in the epilepsy market and are expected to provide greater efficacy and safety than previous AEDs. The launch and uptake of these new pipeline therapies with better efficacy are expected to drive APAC market growth.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Marketed Products

4 Pipeline Analysis

5 Clinical Trial Analysis

6 Multi-scenario Forecast

7 Drivers and Barriers

8 Deals and Strategic Consolidations

9 Appendix

Companies Mentioned

  • BIAL-Portela
  • Eisai
  • GSK
  • GW Pharmaceuticals
  • Pfizer
  • SK Biopharmaceuticals
  • UCB
  • Zogenix

For more information about this report visit

View source version on

Editor Details

Last Updated: 12-Dec-2018